ViiV Healthcare’s Apretude (cabotegravir long-acting injectable and tablets) Receives EC’s Approval for HIV Prevention
Shots:
- The approval was based on the results from two P-IIb/III active-controlled studies (HPTN 083 & 84) evaluating cabotegravir LA vs oral FTC/TDF tablets (200 mg/300 mg) for PrEP in HIV- men who have sex with men, transgender women and cisgender women at increased risk of sexually acquired HIV
- The results showed that cabotegravir LA was superior to daily oral FTC/TDF tablets & experienced a 69% & 90% lower rate of HIV acquisition vs FTC/TDF tablets in (HPTN 083) & (HPTN 084) trial
- Cabotegravir LA was approved for use in the US, Australia, South Africa & number of other countries, as Apretude for PrEP while the submission to other regulatory agencies is on-going
Ref: ViiV Healthcare| Image: ViiV Healthcare
Related News:- ViiV Healthcare’s Apretude (cabotegravir) Receives US FDA’s Approval for the Prevention of HIV
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
